country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P992535

Copy Link Print Information

JANX-007

JANX-007 is a tumor protease-activated anti-PSMA x CD3 bispecific T cell engager (BiTE). After JANX-007 is cleaved by tumor-specific proteases in the tumor microenvironment to remove the mask, CD3 is exposed, recruiting T cells to kill PSMA-positive tumor cells, and the activated and released TCE fragment can be rapidly cleared. JANX-007 can be used in cancer-related research, such as metastatic castration-resistant prostate cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

JANX-007 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Species Reactivity
- In Vitro
- Target
- Conjugated
- Anwendung
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Species Reactivity

Human

In Vitro

JANX-007 exerts its function after tumor protease cleavage of the linker sequence removes the mask and albumin-binding domain, thereby mediating tumor cell killing; the activated TCE fragment released from the tumor is designed to be rapidly cleared in circulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Target

PSMA & CD3

Conjugated

Unconjugated

Anwendung

ELISA, FACS, Functional assay

Chemical Information

SMILES

[JANX-007]
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Zhang J, et al. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies. Cancers. 2024 Sep 06;16(17):3098.

[2]. Hudson A, et al. A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2026 Jan 06;96(1):5.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen